Venture Certified
| 벤처투자유형 | 2021-08-04 ~ 2024-08-03 | 20210804010081 | 2021-08-04 |
| 벤처투자유형 | 2024-08-04 ~ 2027-08-03 | 20240710010024 | 2021-08-04 |
Revenue CAGR +34.5%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 3.3B | 3.2B | 1.8B |
| Operating Profit | -23.3B | -15.4B | -6.1B |
| Net Profit | -21.7B | -14.5B | -5.9B |
| Total Assets | 126.6B | 27.4B | 41.4B |
| Total Liabilities | 2.8B | 1.9B | 1.5B |
| Total Equity | 123.8B | 25.5B | 39.9B |
Operating Loss: Op. profit -23B
3 Consecutive Years of Net Loss
▲ 30.6%
▼ 116.8%
▼ 74.3%
▼ 59.4%
▲ 50.8%
| Name | Position | Role |
|---|---|---|
| 강재우 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 성동구",
"ceo_name": "강재우",
"certificate": [
{
"cert_number": "20210804010081",
"changes": "",
"disclosure_date": "2021-08-04",
"first_cert_date": "2021-08-04",
"no": "1",
"type": "벤처투자유형",
"valid_period": "2021-08-04 ~ 2024-08-03"
},
{
"cert_number": "20240710010024",
"changes": "소재지",
"disclosure_date": "2024-07-10",
"first_cert_date": "2021-08-04",
"no": "2",
"type": "벤처투자유형",
"valid_period": "2024-08-04 ~ 2027-08-03"
}
],
"company_name": "(주)아이젠사이언스",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 164502000,
"cost_of_sales": 0,
"current_assets": 4070031000,
"current_liabilities": 35442000,
"gross_profit": 180000000,
"net_income": -586201000,
"net_income_bs": -586201000,
"non_current_assets": 72806000,
"non_current_liabilities": 112644000,
"non_operating_expenses": 0,
"non_operating_income": 19965000,
"operating_profit": -606166000,
"revenue": 180000000,
"sga_expenses": 786166000,
"total_assets": 4142837000,
"total_equity": 3994751000,
"total_liabilities": 148086000
},
"2023": {
"capital_stock": 164503000,
"cost_of_sales": 0,
"current_assets": 2685594000,
"current_liabilities": 36193000,
"gross_profit": 318687000,
"net_income": -1445091000,
"net_income_bs": -1445091000,
"non_current_assets": 55123000,
"non_current_liabilities": 154863000,
"non_operating_expenses": 0,
"non_operating_income": 99767000,
"operating_profit": -1544858000,
"revenue": 318687000,
"sga_expenses": 1863545000,
"total_assets": 2740717000,
"total_equity": 2549661000,
"total_liabilities": 191056000
},
"2024": {
"capital_stock": 250328000,
"cost_of_sales": 0,
"current_assets": 12108769000,
"current_liabilities": 90777000,
"gross_profit": 325671000,
"net_income": -2171809000,
"net_income_bs": -2171809000,
"non_current_assets": 550393000,
"non_current_liabilities": 190482000,
"non_operating_expenses": 9580000,
"non_operating_income": 169723000,
"operating_profit": -2331952000,
"revenue": 325671000,
"sga_expenses": 2657623000,
"total_assets": 12659162000,
"total_equity": 12377903000,
"total_liabilities": 281259000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "1,000,005,312",
"changes": "1,000,005,312",
"date": "2022-09-26"
},
{
"amount": "100,000,000",
"changes": "100,000,000",
"date": "2021-07-02"
}
],
"main_products": "인공지능기간 신약개발플랫폼 및 혁신신약",
"phone": "02-6952-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |